Cleaved-MMP15 (Y132) Antibody

What is the Cleaved-MMP15 (Y132) antibody and what specific epitope does it recognize?

The Cleaved-MMP15 (Y132) antibody specifically recognizes the fragment of activated MMP-15 protein resulting from cleavage adjacent to tyrosine 132 (Y132). This antibody was produced against a synthesized peptide derived from the internal region of human MMP15, specifically amino acids 113-162 . The antibody is designed to detect the endogenous levels of the activated form of MMP-15, which plays a crucial role in extracellular matrix degradation . The specificity for the cleaved form makes this antibody valuable for studying MMP15 activation states in various physiological and pathological processes.

What forms of Cleaved-MMP15 (Y132) antibodies are commercially available and how should I choose between them?

Cleaved-MMP15 (Y132) antibodies are available in both polyclonal and monoclonal forms:

Selection should be based on your experimental requirements. Use polyclonal antibodies when higher sensitivity is needed or when studying proteins with low expression levels. Choose monoclonal antibodies when absolute specificity is critical, especially in experiments requiring reproducibility across multiple studies . For studies focusing specifically on activation states of MMP15, the polyclonal version might offer better detection of various cleaved forms.

What is the molecular weight of cleaved MMP15 and how does it differ from the precursor form?

The observed molecular weight of cleaved MMP15 is approximately 61 kDa as detected in Western blot analyses, while the calculated molecular weight of the full-length protein is 76 kDa . This difference reflects the proteolytic processing that occurs during MMP15 activation. The precursor of MMP15 (pro-MMP15) contains a conserved cysteine in the cysteine-switch motif that binds to the catalytic zinc ion, thereby maintaining the enzyme in an inactive state. Upon activation, the precursor is cleaved by a furin endopeptidase, resulting in the removal of the inhibitory pro-domain and generating the mature, active form of the enzyme . This cleavage event leads to the dissociation of the cysteine from the zinc ion, activating the enzyme and resulting in the smaller observed molecular weight.

What are the validated applications for Cleaved-MMP15 (Y132) antibodies and what are the recommended dilutions?

Based on manufacturer validation data, the primary applications for Cleaved-MMP15 (Y132) antibodies are:

These antibodies have been extensively tested in these applications with consistent results across different cell lines, including COS7, MCF-7, SGC7901, HCT116, and HEK293T . Other potential applications such as immunohistochemistry, immunofluorescence, and immunoprecipitation have not been thoroughly validated by manufacturers and would require optimization by individual researchers .

How should I optimize Western blot protocols when using Cleaved-MMP15 (Y132) antibodies?

For optimal Western blot results with Cleaved-MMP15 (Y132) antibodies, consider the following protocol adjustments:

• Sample preparation:

  • Use cell lysates from tissues known to express MMP15 (liver, placenta, testis, colon, intestine)

  • Consider treatment with activators such as etoposide (25μM for 1 hour) to increase cleaved MMP15 levels

• Gel separation:

  • Use 10% SDS-PAGE gels for optimal separation around the 61 kDa range

  • Include positive controls such as COS7 cells treated with etoposide

• Transfer and blocking:

  • Use PVDF membranes for better protein retention

  • Block with 5% non-fat milk or BSA in TBST for 1-2 hours at room temperature

• Antibody incubation:

  • Primary antibody: Dilute to 1:500-1:2000 in blocking buffer

  • Incubate overnight at 4°C with gentle agitation

  • Secondary antibody: Anti-rabbit or anti-mouse HRP conjugate at 1:5000-1:10000

• Detection:

  • Use enhanced chemiluminescence (ECL) for detection

  • Expected band: 61 kDa for cleaved MMP15

For validation, consider using a blocking peptide control with the synthesized immunogenic peptide to confirm specificity, as demonstrated in manufacturer validation data .

What cell lines and treatment conditions are optimal for studying MMP15 activation using these antibodies?

Based on the provided validation data and MMP15 tissue expression patterns, the following cell lines and treatment conditions are recommended for studying MMP15 activation:

To optimize detection of the cleaved form, consider treatments that induce stress or stimulate protease activity. Etoposide treatment (25μM for 1 hour) has been validated to increase detection of cleaved MMP15 (Y132) . Additionally, cytokine stimulation or growth factor treatments may enhance MMP15 expression and subsequent activation. Verification of MMP15 expression levels in your specific cell line before antibody-based experiments is recommended through qPCR analysis .

How can I distinguish between active and inactive forms of MMP15 in complex tissue samples?

Distinguishing between active and inactive forms of MMP15 in complex tissue samples requires a multi-faceted approach:

• Immunoblotting with form-specific antibodies:

  • Use Cleaved-MMP15 (Y132) antibody to detect active form (61 kDa)

  • Use total MMP15 antibodies to detect both pro-form (76 kDa) and active form

  • The ratio between these forms can indicate activation status

• Gelatin zymography with modifications:

  • Incorporate MMP15 substrates in zymography gels

  • Active MMP15 will produce clear bands of degradation

  • Pro-form may show weaker or no activity

• Co-immunoprecipitation with TIMP-2:

  • TIMPs (Tissue Inhibitors of Metalloproteinases) preferentially bind active MMPs

  • IP with anti-TIMP-2 followed by Western blot with anti-MMP15

• Functional activity assays:

  • Use fluorogenic peptide substrates specific for MMP15

  • Measure enzymatic activity in tissue extracts

  • Compare activity before and after activation with APMA (p-aminophenylmercuric acetate)

• Subcellular fractionation:

  • Membrane fractions will contain both forms

  • Extracellular fractions may contain processed active forms

  • Use the Cleaved-MMP15 (Y132) antibody to track localization changes

This combined approach provides comprehensive information about MMP15 activation status in complex tissue environments .

What are the key mechanisms of MMP15 activation and how can the Cleaved-MMP15 (Y132) antibody help elucidate these pathways?

MMP15 activation involves several key mechanisms that can be studied using the Cleaved-MMP15 (Y132) antibody:

• Proteolytic processing: The primary activation mechanism involves cleavage by furin endopeptidase, which removes the inhibitory pro-domain. The Cleaved-MMP15 (Y132) antibody specifically recognizes this activation event by detecting the cleaved form at Y132 .

• Zinc-cysteine coordination: The conserved cysteine in the cysteine-switch motif binds the catalytic zinc ion in the pro-form, inhibiting enzyme activity. Upon activation, this interaction is disrupted. Researchers can use the antibody to track this conformational change by examining cleaved MMP15 levels under conditions that affect zinc homeostasis .

• Cell surface localization: As a membrane-type MMP, proper trafficking to the cell surface is crucial for MMP15 function. The antibody can be used in immunofluorescence studies to visualize the localization of activated MMP15 at the cell membrane .

• Activation cascades: MMP15 may activate other MMPs, particularly progelatinase A. Co-immunoprecipitation experiments using the Cleaved-MMP15 (Y132) antibody can identify interaction partners in these activation cascades .

• Regulatory pathways: Various signaling pathways (MAPK, Wnt, NFκB) can influence MMP15 expression and activation. Western blot analysis with the antibody can quantify activation levels after manipulation of these pathways, helping to establish regulatory mechanisms .

By employing the Cleaved-MMP15 (Y132) antibody in these experimental contexts, researchers can gain insights into the complex regulation of MMP15 activation and its role in both physiological and pathological processes.

How does MMP15 activation differ between normal tissue remodeling and pathological conditions such as cancer?

The activation patterns and functions of MMP15 show distinct differences between normal tissue remodeling and pathological conditions:

The Cleaved-MMP15 (Y132) antibody can be valuable in comparative studies of these differences by specifically detecting the activated form. In cancer tissues, researchers often observe higher levels of the cleaved 61 kDa form compared to matched normal tissues, indicating dysregulated activation. Studies in breast, colorectal, and glottis squamous cell carcinomas have shown correlations between cleaved MMP15 levels and invasion potential .

In normal physiological contexts like embryonic development and tissue remodeling, the activation of MMP15 follows precise spatiotemporal patterns that can be mapped using the Cleaved-MMP15 (Y132) antibody in developmental studies, revealing the regulated nature of MMP15 function in normal biology versus its more chaotic activation in pathological states.

What are common issues when using Cleaved-MMP15 (Y132) antibodies and how can they be resolved?

Researchers may encounter several technical challenges when working with Cleaved-MMP15 (Y132) antibodies:

• Low or no signal in Western blots:

  • Cause: Insufficient MMP15 expression or activation in samples

  • Solution: Use positive control tissues (liver, placenta); treat cells with activators like etoposide (25μM, 1h); increase protein loading to 40-60μg

• Multiple bands or high background:

  • Cause: Cross-reactivity or non-specific binding

  • Solution: Increase antibody dilution (1:1000-1:2000); optimize blocking (5% BSA instead of milk); add 0.1% Tween-20 to antibody diluent; increase washing steps

• Inconsistent results between experiments:

  • Cause: Variability in MMP15 activation status

  • Solution: Standardize sample collection and processing; include internal loading controls; use freshly prepared lysates

• Discrepancy between observed and expected molecular weight:

  • Cause: Post-translational modifications or processing variations

  • Solution: Use protein ladders with close range markers; include both positive controls and blocking peptide controls

• Lack of signal in immunohistochemistry:

  • Cause: Epitope masking during fixation

  • Solution: Optimize antigen retrieval methods; try different fixation protocols; consider using frozen sections instead of paraffin-embedded tissues

When troubleshooting, remember that storage conditions are critical - avoid repeated freeze-thaw cycles of the antibody, and store at -20°C as recommended by manufacturers .

How can I validate the specificity of Cleaved-MMP15 (Y132) antibody results in my experimental system?

Validating the specificity of Cleaved-MMP15 (Y132) antibody results requires a multi-layered approach:

• Blocking peptide control:

  • Perform parallel Western blots with and without pre-incubation of the antibody with the immunizing peptide

  • The specific 61 kDa band should disappear or significantly diminish in the blocked sample

  • This approach is demonstrated in manufacturer validation data where blocking peptide eliminated specific signals

• siRNA or CRISPR knockdown of MMP15:

  • Transfect cells with MMP15-specific siRNA or generate CRISPR knockout models

  • The cleaved MMP15 band should be reduced or absent in knockdown/knockout samples

  • Include scrambled siRNA or wild-type cells as controls

• Overexpression validation:

  • Transfect cells with MMP15 expression constructs

  • Compare transfected versus non-transfected cells in Western blot

  • Should observe increased intensity of the 61 kDa band

• Correlation with other detection methods:

  • Compare results with alternative antibodies targeting different MMP15 epitopes

  • Validate with orthogonal techniques like mass spectrometry

  • Correlate protein detection with mRNA expression (qRT-PCR)

• Functional validation:

  • Treat samples with known MMP inhibitors and observe decreased levels of cleaved form

  • Induce conditions known to activate MMPs and confirm increased cleaved MMP15

This comprehensive validation approach ensures that signals detected by the Cleaved-MMP15 (Y132) antibody are indeed specific to the activated form of MMP15 .

What considerations should be made when studying MMP15 in different species or tissue types?

When extending MMP15 research across species or diverse tissue types, several important considerations must be addressed:

• Species reactivity limitations:

  • Cleaved-MMP15 (Y132) antibodies are validated for human and non-human primate samples

  • Mouse reactivity is limited or unverified for most commercial antibodies

  • For rodent studies, confirm epitope conservation or seek species-specific alternatives

• Tissue-specific expression patterns:

  • Highest expression in liver, placenta, testis, colon, and intestine

  • Moderate expression in pancreas, kidney, lung, heart, and skeletal muscle

  • For low-expressing tissues, sensitivity may require optimization (increased protein loading, more sensitive detection methods)

• Extraction methods by tissue type:

  • Fibrous tissues (muscle, skin): Require more aggressive homogenization

  • Lipid-rich tissues (brain, adipose): Need detergent modifications

  • Membrane fractionation may be necessary for optimal MMP15 extraction

• Fixation and processing considerations:

  • Fresh-frozen samples generally yield better results than formalin-fixed

  • Antigen retrieval requirements differ by tissue type

  • Excessive fixation may mask the Y132 epitope

• Background considerations:

  • High vascularity tissues may show increased background

  • Endogenous peroxidase activity varies by tissue and requires appropriate quenching

  • Tissue-specific autofluorescence requires different blocking strategies

When expanding to new tissue types, preliminary experiments should include positive control tissues with known MMP15 expression to validate detection methods. Additionally, complementary approaches like RT-PCR can confirm MMP15 expression before investing in protein-level studies in novel tissue contexts .

How can Cleaved-MMP15 (Y132) antibodies be used to investigate the role of MMP15 in cancer progression and metastasis?

Cleaved-MMP15 (Y132) antibodies offer powerful tools for investigating MMP15's role in cancer biology through several methodological approaches:

• Biomarker analysis in patient samples:

  • Quantify cleaved MMP15 levels in tumor versus adjacent normal tissue

  • Correlate activation status with clinical parameters (stage, grade, invasion depth)

  • Perform survival analysis based on cleaved/total MMP15 ratios

  • Particularly relevant for glottis squamous cell carcinoma and supraglottis cancer where MMP15 has established associations

• Invasion and migration studies:

  • Monitor MMP15 activation during in vitro invasion assays

  • Use time-course Western blots with the Cleaved-MMP15 (Y132) antibody

  • Correlate cleaved MMP15 levels with invasion capacity

  • Combine with zymography to link activation to matrix degradation

• Therapeutic targeting validation:

  • Assess MMP15 activation status after treatment with experimental inhibitors

  • Use the antibody to confirm target engagement in drug development

  • Monitor changes in cleaved/total MMP15 ratio as pharmacodynamic markers

• Mechanism studies:

  • Investigate microenvironmental factors that trigger MMP15 activation in tumors

  • Examine hypoxia, inflammatory cytokines, or stromal interactions

  • Use co-immunoprecipitation with the Cleaved-MMP15 (Y132) antibody to identify cancer-specific interaction partners

• Metastasis research:

  • Compare cleaved MMP15 levels between primary tumors and metastatic lesions

  • Use the antibody in immunohistochemistry to visualize activated MMP15 at invasion fronts

  • Develop prognostic models incorporating cleaved MMP15 status

This antibody enables researchers to move beyond mere expression studies to focus specifically on the functionally relevant activated form of MMP15, providing deeper insights into its mechanistic role in cancer progression .

What methods can be used to study the interplay between MMP15 and other matrix metalloproteinases using these antibodies?

Understanding the complex interplay between MMP15 and other matrix metalloproteinases requires sophisticated experimental approaches utilizing Cleaved-MMP15 (Y132) antibodies:

• Sequential activation cascade analysis:

  • MMP15 may activate progelatinase A (pro-MMP2)

  • Use dual-immunoblotting with Cleaved-MMP15 (Y132) and activated MMP2 antibodies

  • Perform time-course experiments to establish activation sequence

  • Confirm with activity assays using specific fluorogenic substrates

• Co-immunoprecipitation studies:

  • Use Cleaved-MMP15 (Y132) antibody for immunoprecipitation

  • Blot for other MMPs (MMP2, MMP9, MMP14) to identify direct interactions

  • Perform reverse co-IP to confirm specificity of interactions

  • Include appropriate controls (IgG, lysate input)

• Proximity ligation assays:

  • Visualize in situ interactions between cleaved MMP15 and other MMPs

  • Combine Cleaved-MMP15 (Y132) antibody with antibodies against other MMPs

  • Quantify interaction signals at different cellular locations

• Inhibitor studies with selective profiling:

  • Apply selective inhibitors for different MMPs

  • Monitor effects on MMP15 activation using the Cleaved-MMP15 (Y132) antibody

  • Establish dependency relationships in the MMP activation network

• TIMP interaction studies:

  • Examine how different TIMPs (TIMP-1, TIMP-2, TIMP-3, TIMP-4) affect MMP15 activation

  • Correlate TIMP levels with cleaved MMP15 detection

  • Perform in vitro TIMP titration experiments

• Multi-MMP activation profiling:

  • Create activation profiles across multiple MMPs in different conditions

  • Use antibody arrays or multiplexed Western blots including Cleaved-MMP15 (Y132)

  • Develop mathematical models of MMP activation networks

These approaches help establish the position of MMP15 within the complex web of metalloproteinase interactions that collectively regulate extracellular matrix remodeling in both physiological and pathological contexts .

How can researchers investigate the relationship between MMP15 activation and extracellular matrix remodeling in disease models?

Investigating the relationship between MMP15 activation and extracellular matrix (ECM) remodeling in disease models requires integrated experimental approaches:

• Correlative tissue analysis:

  • Perform sequential sections or multiplex immunostaining with:

    • Cleaved-MMP15 (Y132) antibody for activation status

    • ECM component antibodies (collagens, fibronectin, laminin)

    • Markers of matrix degradation (neoepitope antibodies)

  • Quantify spatial relationships between activated MMP15 and ECM degradation

• 3D cell culture models:

  • Establish cells in 3D matrices (collagen, Matrigel, or tissue-specific ECM)

  • Monitor MMP15 activation during matrix invasion using the Cleaved-MMP15 (Y132) antibody

  • Correlate with real-time visualization of matrix degradation using fluorescently labeled ECM

  • Perform gain/loss-of-function experiments with MMP15 constructs

• In vivo models with temporal sampling:

  • Use disease models relevant to MMP15 (cancer, fibrosis, inflammatory conditions)

  • Collect samples at different disease stages

  • Analyze cleaved MMP15 levels by Western blot

  • Correlate with histopathological assessment of ECM remodeling

  • Consider inducible MMP15 knockout or overexpression models

• Substrate specificity profiling:

  • Identify disease-relevant MMP15 substrates using:

    • Proteomic approaches with MMP15-expressing versus control cells

    • In vitro cleavage assays with recombinant MMP15

    • Validation by monitoring substrate degradation when MMP15 is activated

  • Use the Cleaved-MMP15 (Y132) antibody to confirm activation status

• Therapeutic intervention studies:

  • Test MMP inhibitors or ECM-targeting therapies

  • Monitor changes in MMP15 activation status

  • Correlate with changes in ECM composition and organization

  • Evaluate functional outcomes in disease progression

By integrating these approaches, researchers can establish causal relationships between MMP15 activation and specific patterns of ECM remodeling in different disease contexts, potentially identifying new therapeutic targets or biomarkers .

What are emerging research areas where Cleaved-MMP15 (Y132) antibodies could provide valuable insights?

Several cutting-edge research areas could benefit from the application of Cleaved-MMP15 (Y132) antibodies:

• Single-cell analysis of MMP activation:

  • Combining Cleaved-MMP15 (Y132) antibodies with single-cell technologies

  • Mass cytometry (CyTOF) or imaging mass cytometry to map MMP15 activation at cellular resolution

  • Correlation with cell states and microenvironmental factors

  • Potential for discovering specialized cellular niches of MMP15 activation

• Exosome and extracellular vesicle biology:

  • Investigating MMP15 incorporation and activation in cancer-derived exosomes

  • Using the antibody to study how activated MMP15 might contribute to pre-metastatic niche formation

  • Potential biomarker applications in liquid biopsies

• Immune cell interactions with the ECM:

  • Exploring how immune cell subsets might activate MMP15 in inflammatory conditions

  • Investigating the role of activated MMP15 in immune cell migration through tissues

  • Potential implications for immunotherapy response prediction

• Biomaterial and regenerative medicine applications:

  • Understanding MMP15 activation during integration or degradation of therapeutic biomaterials

  • Developing MMP15-responsive smart materials that respond to specific activation states

  • Engineering more biocompatible materials by accounting for MMP15 activity

• Spatial multi-omics integration:

  • Combining Cleaved-MMP15 (Y132) antibody-based imaging with spatial transcriptomics

  • Creating comprehensive maps of MMP activation networks in complex tissues

  • Potential for discovering new regulatory mechanisms of MMP15 activation

These emerging areas represent opportunities for researchers to apply Cleaved-MMP15 (Y132) antibodies in novel ways that could significantly advance our understanding of MMP biology in health and disease .

What methodological advances might improve detection and quantification of cleaved MMP15 in complex biological samples?

Future methodological advances could significantly enhance the study of cleaved MMP15:

• Enhanced antibody technologies:

  • Development of recombinant antibodies with increased specificity and sensitivity

  • Nanobodies or single-chain antibodies with improved tissue penetration

  • Bifunctional antibodies that simultaneously detect cleaved MMP15 and its substrates

  • FRET-based antibody systems for real-time activation monitoring

• Advanced imaging approaches:

  • Super-resolution microscopy techniques to visualize MMP15 activation at nanoscale resolution

  • Intravital imaging with activation-specific reporters

  • Label-free detection methods such as Raman spectroscopy to identify MMP15 activation states

  • AI-assisted image analysis for quantitative assessment of activation patterns

• Improved biochemical detection:

  • Development of ultrasensitive ELISA or digital ELISA (Simoa) for cleaved MMP15 detection in biofluids

  • Multiplex platforms combining cleaved MMP15 with other relevant biomarkers

  • Aptamer-based detection technologies with improved sensitivity

  • Mass spectrometry workflows optimized for membrane-associated MMPs

• Functional readouts:

  • Activity-based probes that specifically report on MMP15 activity

  • Real-time sensors for MMP15 activation in living systems

  • Microfluidic platforms for kinetic studies of MMP15 activation

  • Biosensor development for continuous monitoring in complex models

• Computational approaches:

  • Machine learning algorithms for pattern recognition in MMP activation networks

  • Systems biology models integrating MMP15 activation with downstream consequences

  • Predictive tools for identifying conditions of MMP15 hyperactivation

These methodological advances would address current limitations in sensitivity, spatial resolution, temporal dynamics, and throughput in cleaved MMP15 analysis, enabling more sophisticated studies of its role in complex biological processes .

How might our understanding of MMP15 activation contribute to therapeutic developments targeting matrix remodeling processes?

Understanding MMP15 activation could significantly impact therapeutic strategies in several ways:

• Targeted inhibitor development:

  • Design of inhibitors specific to the activated form of MMP15

  • Structure-based drug design leveraging the unique conformation of cleaved MMP15

  • Development of inhibitors that block the activation site (Y132) rather than the catalytic site

  • Potential for reducing off-target effects compared to broad-spectrum MMP inhibitors

• Diagnostic and patient stratification applications:

  • Development of companion diagnostics measuring cleaved MMP15 levels

  • Identification of patient subgroups likely to benefit from MMP-targeting therapies

  • Monitoring of treatment efficacy through quantification of cleaved/total MMP15 ratios

  • Liquid biopsy applications for non-invasive monitoring

• Delivery system innovations:

  • MMP15 activation-responsive drug delivery systems

  • Nanoparticles that release therapeutic cargo upon encountering activated MMP15

  • Targeting drugs specifically to microenvironments with high MMP15 activity

  • Reduced systemic toxicity through environment-specific activation

• Combination therapy approaches:

  • Rational combinations of MMP15 inhibitors with existing therapies

  • Potential synergies with immune checkpoint inhibitors in cancer

  • Sequential therapy approaches timed to MMP15 activation patterns

  • ECM-normalization strategies to improve drug delivery

• Tissue engineering and regenerative medicine:

  • Harnessing controlled MMP15 activation for scaffold remodeling

  • Engineering smart biomaterials responsive to MMP15 activity

  • Temporal control of matrix remodeling in tissue regeneration

  • Balance between beneficial and detrimental MMP15 activity